The U.S. Food and Drug Administration released two policy moves that could reshape early‑stage development and regenerative medicine pathways: draft guidance encouraging reduced reliance on animal studies for certain toxicology assessments, and a procedural change allowing consideration of RMAT (Regenerative Medicine Advanced Therapy) designations for programs on clinical hold. The draft guidance outlines approaches to validate alternative methods for toxicology and early safety, signaling regulatory openness to new non‑animal assays and in vitro models. Separately, the RMAT clarification gives developers of cell and gene therapies potential access to designation benefits even when a program faces a clinical hold, a change aimed at preserving expedited pathways while regulators and sponsors resolve safety or manufacturing issues. Both actions were framed by the FDA as steps to modernize review paradigms and accelerate patient access, but they will require sponsors to engage early with regulators to align validation evidence and risk‑management plans.